Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 6/20 | 0.46 |
| ▸ | VRK1 | Q99986 | 6/20 | 0.43 |
| ▸ | VRK2 | Q86Y07 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.43 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.43 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16178700 | 0.74 | RPS6KA3 (0.47) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL16178560 | 0.72 | RPS6KA3 (0.58) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL12345550 | 0.72 | RPS6KA3 (0.58) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL13104981 | 0.71 | RPS6KA3 (0.49) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL13814860 | 0.71 | MAPT (0.39) | VRK1 | |
| SCHEMBL4076168 | 0.71 | RPS6KA3 (0.42) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL21493004 | 0.69 | VRK1 (0.46) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL21492526 | 0.67 | STK4 (0.50) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL21261610 | 0.67 | STK4 (0.50) | RPS6KA3VRK1VRK2JAK2BRD4 | |
| SCHEMBL3543954 | 0.67 | RPS6KA3 (0.45) | RPS6KA3VRK1VRK2JAK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547780-B2 | Cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent; leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases, arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | GRAUERT MATTHIAS | 2008-08-14 | — | — | US | disclosed |
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-15 | — | — | US | disclosed |
| US-20080108812-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-08 | — | — | US | disclosed |
| US-7332491-B2 | cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent: leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases: arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | QDPR, DHPS, DHODH | RPS6KA3 554/4885VRK1 4130/4885VRK2 3862/4885 |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | CCNK, CDK1, PLK1 | RPS6KA3 20/4885VRK1 528/4885VRK2 588/4885 |
| US-20080108812-A1 | Dihydropteridione Intermediate Compounds | QDPR, DHPS, DHODH | RPS6KA3 554/4885VRK1 4130/4885VRK2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.